TERN_201



NAME OF DRUG : TERN_201

ALSO KNOWN AS : TERN_201

LABORATORY : TERNS

STATUS AND ADVANCEMENT

Type of drug : SSAO Inhibitor

Clinical trials advancement : Recruiting Phase 1

Estimated time to market : 134 months.

LABORATORY ABSTRACT ON THE DRUG

SSAO, also known as VAP-1 (Vascular Adhesion Protein-1), is a dual-function amine oxidase which promotes recruitment of white blood cells in the liver, and can result in increased oxidative stress, inflammation and hepatic fibrosis. The level of surface SSAO is upregulated in the vasculature of inflamed tissues, and soluble SSAO levels are elevated in patients with NASH. Inhibition of SSAO is believed to have therapeutic benefit for the treatment of NAFLD, NASH and other chronic fibrotic liver diseases. TERN-201 is a potent SSAO inhibitor which may provide an additional treatment mechanism for NASH by reducing oxidative stress and recruitment of white blood cells to the liver.

HISTORY AND ANALYSIS

TERNS PHARMACEUTICALS, INC. is a ELI LILLY company

 

RECENT NEWS ON TERN_201

SOME PUBLICATIONS RELATED WITH TERN_201

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH TERN_201


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE